Santen Pharmaceutical Co Ltd (SNPHY)
OTHER OTC:SNPHY
Want to see SNPHY full AI Analyst Report?
Top Page
Santen Pharmaceutical Co
(OTC:SNPHY)
Select Model
Select Model
Rating:65Neutral
Price Target:
$13.00
▲(18.18% Upside)
Action:ReiteratedDate:02/08/26
The score is primarily driven by financial performance: strong leverage profile and profitability are offset by a pronounced TTM revenue decline and softer cash-flow momentum. Technicals and valuation are both neutral-to-slightly positive, offering limited additional support.
Positive Factors
Conservative Balance Sheet
Santen’s low debt-to-equity (~0.13) and sizable equity base provide enduring financial flexibility. This conservative financing lowers refinancing risk, supports continued R&D and manufacturing investment, and creates capacity to absorb shocks or pursue strategic deals without levering up.
Negative Factors
Sharp Revenue Decline
A ~-74% TTM revenue contraction is a material structural headwind: it erodes market share, limits scale benefits, and undermines the sustainability of margins and R&D funding. Restoring top-line growth is essential for long-term earnings durability and competitive positioning.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Santen’s low debt-to-equity (~0.13) and sizable equity base provide enduring financial flexibility. This conservative financing lowers refinancing risk, supports continued R&D and manufacturing investment, and creates capacity to absorb shocks or pursue strategic deals without levering up.
Read all positive factors
Santen Pharmaceutical Co (SNPHY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.31B
Dividend Yield2.02%
Average Volume (3M)1.01K
Price to Earnings (P/E)16.3
Beta (1Y)>-0.01
Revenue Growth-3.51%
EPS Growth19.47%
CountryUS
Employees3,744
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.16
Shares Outstanding322,281,650
10 Day Avg. Volume2,904
30 Day Avg. Volume1,010
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.73
Price to Sales (P/S)1.65
P/FCF Ratio9.12
Enterprise Value/Market Cap152.75
Enterprise Value/Revenue1.74
Enterprise Value/Gross Profit3.14
Enterprise Value/Ebitda8.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Santen Pharmaceutical Co Business Overview & Revenue Model
Company Description
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-11...
How the Company Makes Money
Santen makes money primarily by selling ophthalmic pharmaceuticals. Its core revenue stream is product sales of prescription eye drops and other eye-disease therapies to wholesalers, hospitals, pharmacies, and other healthcare channels, with reven...
Santen Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 290.51B | 300.00B | 301.96B | 279.04B | 266.26B | 249.60B |
| Gross Profit | 160.92B | 171.03B | 178.71B | 166.09B | 156.59B | 151.38B |
| EBITDA | 61.76B | 59.01B | 50.72B | 12.95B | 52.93B | 70.28B |
| Net Income | 30.89B | 36.26B | 26.64B | -14.95B | 27.22B | 6.83B |
Balance Sheet | ||||||
| Total Assets | 401.43B | 409.28B | 435.70B | 421.18B | 459.98B | 402.35B |
| Cash, Cash Equivalents and Short-Term Investments | 61.59B | 93.99B | 94.96B | 58.68B | 84.31B | 63.41B |
| Total Debt | 36.17B | 34.23B | 35.16B | 36.21B | 32.93B | 10.15B |
| Total Liabilities | 118.81B | 124.10B | 130.33B | 127.88B | 123.13B | 95.30B |
| Stockholders Equity | 283.58B | 286.24B | 306.06B | 293.98B | 337.49B | 307.58B |
Cash Flow | ||||||
| Free Cash Flow | 30.10B | 54.27B | 61.96B | 12.56B | 10.20B | 15.00B |
| Operating Cash Flow | 34.21B | 60.93B | 72.65B | 37.15B | 46.04B | 38.81B |
| Investing Cash Flow | -10.60B | -8.22B | -6.14B | -26.78B | -35.17B | -53.35B |
| Financing Cash Flow | -34.15B | -53.31B | -34.03B | -37.22B | 5.56B | -16.68B |
Santen Pharmaceutical Co Technical Analysis
Positive
11.00
Price Trends
11.02
Positive
10.80
Positive
10.75
Positive
Market Momentum
0.14
Positive
50.18
Neutral
1.17
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNPHY, the sentiment is Positive. The current price of 11 is below the 20-day moving average (MA) of 11.29, below the 50-day MA of 11.02, and above the 200-day MA of 10.75, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 50.18 is Neutral, neither overbought nor oversold. The STOCH value of 1.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNPHY.
Santen Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $123.71B | 15.61 | 39.27% | 4.11% | -0.22% | ― | |
71 Outperform | £216.31B | 28.13 | 23.00% | 1.53% | 4.64% | 26.75% | |
69 Neutral | $112.74B | 15.55 | 14.41% | 4.58% | 11.19% | -0.23% | |
68 Neutral | $104.75B | 13.19 | 37.19% | 3.41% | 9.19% | 98.98% | |
65 Neutral | $3.31B | 16.26 | 10.88% | 2.02% | -3.51% | 19.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $6.56B | 14.03 | 7.56% | 1.56% | 9.11% | 170.10% |
* Healthcare Sector Average
SNPHY
Santen Pharmaceutical Co
10.31
0.08
0.74%
BMY
Bristol-Myers Squibb
60.59
12.43
25.80%
GSK
GlaxoSmithKline
52.31
14.74
39.22%
GRFS
Grifols SA
8.24
0.99
13.66%
SNY
Sanofi
46.58
-7.15
-13.30%
GB:AZN
AstraZeneca
13,948.00
3,378.22
31.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.